Introduction Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) (e.g., Semaglutide (Ozempic) and Tirzepatide (Mounjaro)) have historically been prescribed to treat Type-2 Diabetes Mellitus (T2DM), but their efficacy in managing weight loss has increased their role in weight management treatments ( At present, the risk of prolonged GLP-1 RA usage as it pertains to the thyroid and the development of medullary thyroid carcinoma (MTC) is unclear
All medications are HSA/FSA eligible, and no membership or insurance is required
Strong dual CYP3A4/P-gp inhibitors (ketoconazole, ritonavir, clarithromycin) can double apixaban exposure [1]
A study that looked into the effect of high doses of ascorbic acid on inflammation in cancer patients concluded that the vitamin significantly reduces inflammatory processes in the most severe patients, while other studies have proven its effect on reducing tumour marker levels
Longer-term scale depends on affordability and movement into reimbursed care
In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided